MONASH IVF GROUP LIMITED — Director's Dealing 2022

Nov 23, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Monash IVF Group Limited

ABN 90 169 302 309

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Damian Knaap
Date of last notice	24 November 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	21 November 2022
No. of securities held prior to change	Indirect interest of 150,655 Ordinary Shares held by MKN Family Holdings Pty Ltd as trustee for the Pakhill Superannuation Fund. Performance Rights • 501,629 under the 2021 Equity Incentive Plan • 466,166 under the 2022 Equity Inventive Plan
Class	Performance Rights
Number acquired	532,599
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	Indirect interest of 150,655 Ordinary Shares held by MKN Family Holdings Pty Ltd as trustee for the Pakhill Superannuation Fund. Performance Rights • 501,629 under the 2021 Equity Incentive Plan • 466,166 under the 2022 Equity Inventive Plan • 532,599 under the 2023 Equity Incentive Plan
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of performance rights as approved at the 2022 Annual General Meeting

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

==> picture [596 x 118] intentionally omitted <==

ASX Announcement

Monash IVF Group Limited (ASX:MVF)

24 November 2022

Appendix 3Y Correction

Monash IVF Group Limited (ASX: MVF, the “Company” or “Monash IVF”) refers to the Appendix 3Y for Mr Michael Knaap released to the market on 21 November 2022. The Appendix 3Y inadvertently overstated the number of performance rights granted to Mr Knaap under the Company’s 2023 Equity Incentive Plan as 540,170 instead of 532,599. A corrected Appendix 3Y is attached to this announcement.

Authorised by the Chairman

For further information please contact:

Michael Knaap

Chief Executive Officer & Managing Director Monash IVF Group T: +61 3 9420 8235

Malik Jainudeen

Chief Financial Officer & Company Secretary Monash IVF Group +61 3 9420 8235

-Ends-